Inhibition of HIV-1 replication by the Cre-loxP hammerhead ribozyme.
Antiviral strategies to suppress productive human immunodeficiency virus type 1 (HIV-1) replication have included the generation of gene products that provide intracellular inhibition of an essential viral protein or RNA. The potential of such a molecular genetic intervention was examined by using the Cre/loxP recombination system. In this study, we constructed a loxP-casstte vector (LTR-ribozyme) and a Cre recombinase expression vector (LTR-Cre). The transcription of the ribozyme and Cre genes was designed to be driven from the LTR promoter. These vectors were transiently transfected into COS cells along with the viral expression vector, and inhibited the expression of viral protein in COS cells. These data further support the potential of this system as a therapeutic agent for HIV-1.
Habu
Y
Y
Department of Industrial Chemistry, Chiba Institute of Technology, 2-17-1 Tsudanuma, Narashino, Chiba 275-0016, Japan.
Miyano-Kurosaki
N
N
Takeuchi
H
H
Matsumoto
N
N
Tamura
Y
Y
Takaku
H
H
D000818:Animals; D019556:COS Cells; D015316:Genetic Therapy; D015658:HIV Infections / Q000628:therapy; D016325:HIV Long Terminal Repeat / Q000235:genetics; D015497:HIV-1 / Q000235:genetics* / Q000502:physiology; D019426:Integrases / Q000235:genetics; D016297:Mutagenesis, Site-Directed; D016337:RNA, Catalytic / Q000235:genetics*; D014162:Transfection; D014764:Viral Proteins / Q000235:genetics; D014779:Virus Replication / Q000235:genetics*
D016337:RNA, Catalytic; D014764:Viral Proteins; C427204:hammerhead ribozyme; C045073:Cre recombinase; D019426:Integrases